|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review addresses this novel scenario, presenting data indicating that S100B levels and/or distribution in the nervous tissue of patients and/or experimental models of different neural disorders, for which the protein is used as a biomarker, are directly related to the progress of the disease: acute brain injury (ischemic/hemorrhagic stroke, traumatic injury), neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis), congenital/perinatal disorders (Down syndrome, spinocerebellar ataxia-1), psychiatric disorders (schizophrenia, mood disorders), inflammatory bowel disease.
|
30144068 |
2019 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
EGb, as an adjunctive treatment, can effectively improve depressive symptoms and reduce expression of serum S100B, which is a marker of brain injury, suggesting that EGb restores neurologic function during the treatment of depression in elderly patients and S100B participates in the therapeutic mechanism.
|
30278520 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study aims to investigate whether the gene polymorphisms and haplotype of AQP4 are associated with serum S100 calcium-binding protein B (S100B) level and clinical symptoms in patients with schizophrenia (SCZ).
|
30618856 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We measured S100B levels in fasting plasma of 39 patients with schizophrenia and 19 adult healthy controls.
|
28435992 |
2018 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, GSK3B, HTR2A, PLA2G4A, and S100B variants may determine an anticipation of SCZ age of onset.
|
29164477 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The levels of S100B, RAGE, and Fas Ligand of drug-naive first episode psychosis patients with schizophrenia were significantly higher than that of the same medicated first episode psychosis patients, indicating that an increase of apoptotic signaling is present at the onset of schizophrenia and is also associated with treatment progress.
|
29875007 |
2018 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alpha1-antitrypsin (A1AT), FAS, Heparin-binding EGF-like Growth Factor (HB-EGF), Insulin-like Growth Factor-1 (IGF-1), Luteinizing Hormone (LH), Macrophage Inflammatory Protein type 1 alpha (MIP-1α), Resitin, S100b, Tissue Inhibitor of Metalloproteinase type 1 (TIMP-1), and Vascular Cell Adhesion Molecule type 1 (VCAM-1) each were partial mediators of depression's association with δ.
|
28594820 |
2017 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings support the hypothesis that glial dysfunction and associated marker protein S100B may contribute to the pathophysiologic development of neurocognitive deficits in the relapsed individuals with schizophrenia.
|
27863321 |
2017 |
|
Down Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
The discovery of neuroinflammatory changes, including dramatic proliferation of activated glia overexpressing a chromosome 2 gene product--the pluripotent immune cytokine interleukin-1 (IL-1)--and a chromosome 21 gene product--S100B--in the brains of fetuses, neonates, and children with DS opened the possibility that early events in Alzheimer pathogenesis were driven by cytokines.
|
23866266 |
2013 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Animal studies have strongly implicated a role of S100B in spatial ability and our recent study of humans found that S100B gene polymorphisms (rs9722, rs1051169, and rs2839357) were associated with schizophrenia patients' spatial ability (as assessed by a block design task and a mental rotation task).
|
22019077 |
2012 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
The receptor for advanced glycation end products (RAGE) is the main receptor for S100B, an astrogial proinflammatory mediator that has been suggested to be involved in the pathophysiology of schizophrenia.
|
22146151 |
2012 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The receptor for advanced glycation end products (RAGE) is the main receptor for S100B, an astrogial proinflammatory mediator that has been suggested to be involved in the pathophysiology of schizophrenia.
|
22146151 |
2012 |
|
Down Syndrome
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HSA21 associated S100B and amyloid precursor protein (APP) levels are simultaneously increased within DS HNPs, their secretions are synergistically enhanced in a paracrine fashion, and overexpressions of these proteins disrupt mitochondrial membrane potentials and redox states.
|
21779383 |
2011 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, associations were found between variations in the S100B gene and schizophrenia as well as bipolar affective disorder.
|
21112154 |
2011 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Calcium-binding protein S100B has been implicated in the pathology of bipolar affective disorder (BPAD) and schizophrenia (SZ).
|
21714070 |
2011 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
These results implicate a role for S100B gene polymorphisms in the cognitive functions of schizophrenia patients and encourage further investigation into spatial disability as an endophenotype of schizophrenia.
|
21070816 |
2011 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results implicate a role for S100B gene polymorphisms in the cognitive functions of schizophrenia patients and encourage further investigation into spatial disability as an endophenotype of schizophrenia.
|
21070816 |
2011 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens.
|
20962330 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
These genes include GRM7, previously associated to major depression disorder and bipolar disorder, SLC6A13, in anxiety disorders, and S100B, SSTR5 and COMT in schizophrenia.
|
20398908 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These genes include GRM7, previously associated to major depression disorder and bipolar disorder, SLC6A13, in anxiety disorders, and S100B, SSTR5 and COMT in schizophrenia.
|
20398908 |
2010 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Significant differences in the subgroup depression (first-episode and recurrent depression) were also shown in 3 genotypes of S100B rs9722 and rs11911834 in patients and control subjects (P < 0.05).
|
19497163 |
2009 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Significant differences in the subgroup depression (first-episode and recurrent depression) were also shown in 3 genotypes of S100B rs9722 and rs11911834 in patients and control subjects (P < 0.05).
|
19497163 |
2009 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE.
|
19103440 |
2009 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The picture is not as clear regarding schizophrenia subtypes in acute states but patients with persistent negative symptoms or deficit syndrome show constant high S100B concentrations.
|
20093730 |
2009 |
|
Down Syndrome
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
We further demonstrate in DS NPCs that S100B is constitutively overexpressed, that overexpression leads to increased reactive oxygen species (ROS) formation and activation of stress response kinases, and that activation of this pathway results in compensatory AQP4 expression.
|
17984171 |
2008 |